Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Lancet

• Publication date

  2007-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(07)60946-5PMID 17602732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 引言 (Introduction)

  2009cited by this paper
• Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer

  2007cited by this paper
• Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update

  2007cited by this paper
• Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31

  2006cited by this paper
• Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR

  2006cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• The epidemiology of genital human papillomavirus infection.

  2006cited by this paper
• Cumulative 5‐year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high‐risk HPV and cytology testing in a primary screening setting

  2005cited by this paper
• Prevention of hepatitis A by Havrix™: a review

  2005cited by this paper
• Prevention of hepatitis A by Havrix™: a review

  2005cited by this paper
• Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring

  2004cited by this paper
• Efficacy and other milestones for human papillomavirus vaccine introduction.

  2004cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• Classification of papillomaviruses.

  2004cited by this paper
• Epidemiologic classification of human papillomavirus types associated with cervical cancer.

  2003cited by this paper
• Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study

  2002cited by this paper
• Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses

  2002cited by this paper
• Statistical approaches to establishing vaccine safety

  2002cited by this paper
• Immunological analyses of human papillomavirus capsids.

  2001cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper
• Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.

  1999cited by this paper
• Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4.

  1997cited by this paper
• Approximately optimal one-parameter boundaries for group sequential trials.

  1987cited by this paper
• Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S.

  1974cited by this paper
• Statistical methods for rates and proportions

  1973cited by this paper

• Human papillomavirus vaccinations’ association to childbirth rates

  2026cites this paper
• Type- and age-specific natural history of high-risk human papillomavirus infections in healthy women: A prospective cohort study in China.

  2026cites this paper
• An mRNA-encoded scFv antibody targeting the helix-α3 of HPV18 E7 oncoprotein as a novel antiviral strategy

  2026cites this paper
• Multivalent display of membrane proteins using HIV-1 Gag VLPs

  2026cites this paper
• Advancements and Future Perspectives of Human Papillomavirus (HPV) Vaccination in Latin America: Insights from Recent Decades

  2025cites this paper
• Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system

  2025cites this paper
• The Past, Present, and Future of Cervical Cancer Vaccines

  2025cites this paper
• Virus-like particles: a versatile and effective vaccine platform

  2025influential citation
• Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports

  2025cites this paper
• Immune responses to human papillomavirus infection and vaccination

  2025cites this paper
• Characterization of Endogenous Retroviral-like Particles Expressed from the Spodoptera frugiperda Sf9 Cell Line

  2025cites this paper
• Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation

  2025cites this paper
• Human Papillomavirus: An Old New History

  2025cites this paper
• Retrospective Analysis of HPV Vaccination Attitudes and Uptake Among Medical Students: Implications for Preventive Healthcare

  2025cites this paper
• Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV‐related diseases: a network meta‐analysis

  2025cites this paper
• Human papillomavirus (HPV) vaccination in women with conisation.

  2025cites this paper
• Factors on Knowledge, Health Beliefs, and Willingness toward Human Papillomavirus Vaccine among Chinese Parents, a cross-sectional study in Ordos City, China

  2025cites this paper
• The h4 coil surface region of human papillomavirus type 58 L1 virus-like particle serves as a potential location for presenting the RG1 epitope peptide

  2025cites this paper
• Sexually transmitted human papillomavirus and related sequelae

  2025cites this paper
• Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care

  2025cites this paper
• Investigating the impact of oxygen concentration on the assembly of human papillomavirus virus like particles

  2025cites this paper
• The Benefits of Human Papillomavirus Vaccination on Men's Health: A Literature Review

  2025cites this paper
• Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development

  2025cites this paper
• Human papillomavirus vaccinations' impact on preterm birth rates.

  2025cites this paper
• Potential health impact and cost-effectiveness of human papillomavirus vaccination in Tunisia: A comparative modeling study

  2025cites this paper
• Vaccines in Dermatology—Present and Future: A Review

  2025cites this paper
• Effect of human papillomavirus (HPV) vaccine on HPV type replacement and sexual behaviors in the post-vaccine era: A cross-sectional study

  2025cites this paper
• Preconception care interventions among adolescents and young adults to prevent adverse maternal, perinatal and child health outcomes: An evidence gap map.

  2024cites this paper
• Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States

  2024cites this paper
• Skin Lesions Caused by HPV—A Comprehensive Review

  2024cites this paper
• IDENTIFYING PLAUSIBLE RANGES FOR DIFFERENTIAL VACCINE EFFICACY ACROSS HIGH- AND LOW-INCOME SETTINGS: A SYSTEMATIC REVIEW, DESCRIPTIVE META-ANALYSIS, AND ILLUSTRATIVE EVIDENCE ANALYSIS

  2024cites this paper
• Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study

  2024cites this paper
• Efficacy and immunogenicity of AS04‐HPV‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide

  2024cites this paper
• Human Papillomavirus (HPV) Infection and Risk Behavior in Vaccinated and Non-Vaccinated Paraguayan Young Women

  2024cites this paper
• Structural biology of the human papillomavirus.

  2024cites this paper
• The AOFOG recommendations on human papillomavirus vaccination in the Asia‐Pacific region

  2024cites this paper
• Disproportionate preponderance of HPV genotypes associated with anogenital warts among HIV-positive MSM

  2024cites this paper
• Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59.

  2024cites this paper
• Validation of a triple‐color pseudovirion‐based neutralization assay for immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine

  2024cites this paper
• Trends in research related to vaccine and cancer prevention from 1992 to 2022: A 30-years bibliometric analysis

  2023cites this paper
• Recent Developments in Human Papillomavirus (HPV) Vaccinology

  2023cites this paper
• Cost‐effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India

  2023cites this paper
• Assembly of Human Papillomavirus 16 L1 Protein in Nicotiana benthamiana Chloroplasts into Highly Immunogenic Virus-Like Particles

  2023cites this paper
• Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.

  2023cites this paper
• Viral Infections of the Oral Cavity in Children

  2023cites this paper
• Low-Grade Cervical Intraepithelial Neoplasia (CIN1) Evolution: Analysis of Opportunistic Preventive Vaccination Role

  2023cites this paper
• Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model

  2023influential citation
• A lef5-deficient baculovirus expression system with no virion contamination and promoting secretion.

  2023cites this paper
• Updates on cervical cancer prevention

  2023cites this paper
• A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models

  2023cites this paper
• Updates on HPV Vaccination

  2023cites this paper
• Self−Assembling Nanovaccine Fused with Flagellin Enhances Protective Effect against Foot−and−Mouth Disease Virus

  2023cites this paper
• Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect

  2023cites this paper
• HPV vaccines induce trained immunity and modulate pro‐inflammatory cytokine expression in response to secondary Toll‐like receptor stimulations

  2023cites this paper
• The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.

  2023cites this paper
• Genital Human Papillomavirus Infection in women from Florianópolis - Santa Catarina, Brazil

  2023cites this paper
• A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages

  2023cites this paper
• The impact of human papilloma virus on human reproductive health and the effect on male infertility: An updated review

  2023cites this paper
• Genetic engineering of baculovirus-insect cell system to improve protein production

  2022cites this paper
• The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health

  2022cites this paper
• Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas

  2022cites this paper
• Attitudes of mothers of pre-adolescent girls on HPV vaccine in Italy. Do we need a turning point?

  2022cites this paper
• OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines

  2022cites this paper
• Human Papillomaviruses-Related Cancers: An Update on the Presence and Prevention Strategies in the Middle East and North African Regions

  2022cites this paper
• The importance of long-term follow up of participants in clinical trials

  2022cites this paper
• Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70

  2022cites this paper
• HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage.

  2022cites this paper
• The Effects of Human Papillomavirus Infection and Vaccination on Cardiovascular Diseases. The US National Health and Nutrition Examination Survey 2003-2016.

  2022cites this paper
• Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs

  2022cites this paper
• Estimativa do impacto econômico da assistência ao Câncer de Colo Uterino avançado em hospital público de referência

  2022cites this paper
• Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology.

  2022cites this paper
• Acceptance of Human Papillomavirus Vaccination and Associated Factors among Girls in Arba Minch Town, Southern Ethiopia, 2020

  2022cites this paper
• Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection

  2022cites this paper
• B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination

  2022cites this paper
• Effect of Health Education on Awareness of HPV Vaccination and its Acceptance Among Postpartum Women

  2022cites this paper
• Immunity after HPV Vaccination in Patients after Sexual Initiation

  2022cites this paper
• Where is the next SARS-CoV-2 variant of concern?

  2022cites this paper
• Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems

  2022cites this paper
• HPV vaccination and cervical cancer screening.

  2022cites this paper
• Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years

  2022cites this paper
• Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus–Vaccinated Women—Results From a Tertiary Referral Center

  2022cites this paper
• Genital infection by Human papillomavirus (HPV) in women from Santa Catarina/Brazil

  2022cites this paper
• Human Papillomavirus (HPV) Entry Inhibitors.

  2022cites this paper
• Oral Papillomatosis: Its Relation with Human Papilloma Virus Infection and Local Immunity—An Update

  2022cites this paper
• Perception and knowledge of human papillomavirus (HPV) vaccine for cervical cancer prevention among fully vaccinated female university students in the era of HPV vaccination: a cross-sectional study

  2021cites this paper
• GII.P16-GII.2 Recombinant Norovirus VLPs Polarize Macrophages Into the M1 Phenotype for Th1 Immune Responses

  2021cites this paper
• Current Take on Systemic Sclerosis Patients’ Vaccination Recommendations

  2021cites this paper
• VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants

  2021cites this paper
• Human Papillomavirus Vaccines.

  2021cites this paper
• Combined Truncations at both N- and C-terminus of Human Papillomavirus Type 58 L1 Enhanced the Yield of Virus-like Particles Produced in a Baculovirus System.

  2021cites this paper
• Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy.

  2021cites this paper
• Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities

  2021cites this paper
• Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland

  2021cites this paper
• Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants

  2021cites this paper
• Yeast Shells Encapsulating Adjuvant AS04 as an Antigen Delivery System for a Novel Vaccine against Toxoplasma Gondii.

  2021cites this paper
• Chapter Two: Literature Review

  2021cites this paper
• Infant Vaccination Does Not Predict Increased Infant Mortality Rate: Correcting Past Misinformation

  2021cites this paper
• Four Simple Biomimetic Mineralization Methods to Improve the Thermostability and Immunogenicity of Virus-like Particles as a Vaccine against Foot-and-Mouth Disease

  2021cites this paper
• Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program

  2021cites this paper
• VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

  2021cites this paper